Skip Navigation


Annals of Oncology Advance Access originally published online on September 13, 2009
Annals of Oncology 2009 20(12):2019; doi:10.1093/annonc/mdp429
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/12/2019    most recent
mdp429v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sahin, U.
Right arrow Articles by Altundag, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sahin, U.
Right arrow Articles by Altundag, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Bone morphogenetic proteins and zoledronic acid

The first 10% of the full text of this article appears below.

We read the letter by Boudou-Rouquette et al. [1] in which they described the . . . [Full Text of this Article]

U. Sahin1, A. Alkan1 and K. Altundag2,*

1 Department of Internal Medicine, Hacettepe University School of Medicine
2 Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey

* (E-mail: altundag66@yahoo.com)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
X. Bertagna, P. Boudou-Rouquette, J. Alexandre, O. Soubrane, and F. Goldwasser
Reply to Bone morphogenetic proteins and zoledronic acid
Ann. Onc., December 1, 2009; 20(12): 2019 - 2019.
[Full Text] [PDF]